Virax Biolabs develops FluoroSpot T-Cell diagnostics and immune profiling solutions to detect immune responses associated with viral diseases and chronic inflammation. Their technology enables precise monitoring of T-cell activity, facilitating the diagnosis of conditions like Long COVID and post-acute infection syndromes.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Monitoring T-cell responses, crucial for diagnosing viral diseases and chronic inflammation, often relies on less sensitive techniques. Existing methods may lack the specificity needed for early and accurate detection of immune dysfunction, especially in conditions like Long COVID and post-acute infection syndromes (PAIS). This can lead to delayed diagnoses and suboptimal treatment strategies.
Solution
Virax Biolabs offers ViraxImmune™, an *in vitro* diagnostic (IVD) platform based on FluoroSpot T-cell technology for high-resolution immune profiling. The platform enables sensitive and specific ex vivo identification of T-cells actively secreting signaling proteins or antibodies. ViraxImmune™ facilitates the detailed study and characterization of both innate and adaptive immune responses, providing insights into disease mechanisms. The platform's assays quantify T-cell activity with high precision, aiding in the diagnosis and monitoring of viral diseases, chronic inflammation, and post-acute infection syndromes.
Target Audience
The primary audience includes clinical laboratories, research institutions, and healthcare providers focused on diagnosing and monitoring immune responses in patients with viral diseases, chronic inflammatory conditions, and post-acute infection syndromes.
Features
- ViraxImmune™ IVD platform for monitoring T cell responses
- ELISpot/FluoroSpot kits with pre-coated plates and reagents for cellular-level immune response analysis
- ViraxImmune™ ImmuneSelect Peptide Pools: Pathogen-specific linear peptides for efficient T cell stimulation
- High-affinity recombinant antibodies for cytokine and biomarker detection in ELISA, flow cytometry, and ELISpot assays
- Capable of identifying 1 in 100,000 cells